DTIL vs. SGMO, FRLN, CLLS, OYST, AURA, TRML, MGTX, STRO, AVXL, and REPL
Should you be buying Precision BioSciences stock or one of its competitors? The main competitors of Precision BioSciences include Sangamo Therapeutics (SGMO), Freeline Therapeutics (FRLN), Cellectis (CLLS), Oyster Point Pharma (OYST), Aura Biosciences (AURA), Tourmaline Bio (TRML), MeiraGTx (MGTX), Sutro Biopharma (STRO), Anavex Life Sciences (AVXL), and Replimune Group (REPL). These companies are all part of the "medical" sector.
Sangamo Therapeutics (NASDAQ:SGMO) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking and earnings.
In the previous week, Precision BioSciences had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 5 mentions for Precision BioSciences and 3 mentions for Sangamo Therapeutics. Precision BioSciences' average media sentiment score of 1.45 beat Sangamo Therapeutics' score of 0.91 indicating that Sangamo Therapeutics is being referred to more favorably in the media.
Precision BioSciences has a net margin of -48.10% compared to Precision BioSciences' net margin of -1,749.06%. Sangamo Therapeutics' return on equity of -131.69% beat Precision BioSciences' return on equity.
Sangamo Therapeutics presently has a consensus target price of $5.67, indicating a potential upside of 812.07%. Precision BioSciences has a consensus target price of $46.33, indicating a potential upside of 266.27%. Given Precision BioSciences' higher probable upside, equities research analysts clearly believe Sangamo Therapeutics is more favorable than Precision BioSciences.
56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 2.8% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 4.0% of Precision BioSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Sangamo Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.
Precision BioSciences has lower revenue, but higher earnings than Sangamo Therapeutics. Precision BioSciences is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Sangamo Therapeutics received 351 more outperform votes than Precision BioSciences when rated by MarketBeat users. However, 67.18% of users gave Precision BioSciences an outperform vote while only 62.71% of users gave Sangamo Therapeutics an outperform vote.
Summary
Precision BioSciences beats Sangamo Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Precision BioSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Precision BioSciences Competitors List
Related Companies and Tools
